In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone

Survey of Ophthalmology

Volumn 50, Issue 6 SUPPL. 1, 2005, Pages

  Stroman, David W ^a   Dajcs, Joseph J ^a   Cupp, Gale A ^a   Schlech, Barry A ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

Antibiotic activity; Antibiotic potency; Antibiotic resistance; in vitro; in vivo; MICs; Moxifloxacin; VIGAMOX

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG ACTIVITY; DRUG POTENCY; ENZYME INHIBITION; EYE INFECTION; HELICOBACTER PYLORI; HUMAN; MEDICAL LITERATURE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; TREPONEMA PALLIDUM;

EID: 27844584957     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2005.06.002     Document Type: Article

References (127)

1. R. Abshire, P. Cockrum, and J. Crider Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment Clin Ther 26 2004 191 196
2. F. Alcaide, L. Calatayud, and M. Santín Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii Antimicrob Agents Chemother 48 2004 4562 4565
3. G. Alexandrakis, E.C. Alfonso, and D. Miller Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones Ophthalmology 107 2000 1497 1502
4. E. Aliprandis, J. Ciralsky, and H. Lai Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits Cornea 24 2005 201 205
5. G.P. Allen The mutant prevention concentration (MPC): a review J Infect Dis Phamacother 6 2003 27 47
6. I.S. Barequet, P. Denton, and G.J. Osterhout Treatment of experimental bacterial keratitis with topical trovafloxacin Arch Ophthalmol 122 2004 65 69
7. A. Bauernfeind Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin J Antimicrob Chemother 40 1997 639 651
8. B. Beigi, W. Westlake, and B. Chang The effect of intracameral, pre-operative antibiotics on microbial contamination of anterior chamber aspirates during phacoemulsification Eye 12 Pt 3a 1998 390 394
9. F. Blanche, B. Cameron, and F.X. Bernard Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases Antimicrob Agents Chemother 40 1996 2714 2720
10. J.M. Blondeau Fluoroquinolones: mechanism of action, classification, and development of resistance Surv Ophthalmol 49 Suppl 2 2004 S73 S78
11. J.M. Blondeau A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones J Antimicrob Chemother 43 Suppl B 1999 1 11
12. J.M. Blondeau, R. Laskowski, and J. Bjarnason Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms Int J Antimicrob Agents 14 2000 45 50
13. J.M. Blondeau, X. Zhao, G. Hansen, and K. Drlica Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 433 438
14. H.M. Blumberg, D. Rimland, and D.J. Carroll Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus J Infect Dis 163 1991 1279 1285
15. F.J. Boswell, J.M. Andrews, and G. Jevons Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J Antimicrob Chemother 50 2002 495 502
16. F.J. Boswell, J.M. Andrews, and R. Wise Bactericidal properties of moxifloxacin and post-antibiotic effect J Antimicrob Chemother 43 Suppl B 1999 43 49
17. D.M. Breines, S. Ouabdesselam, and E.Y. Ng Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV Antimicrob Agents Chemother 41 1997 175 179
18. O. Cekiç, C. Batman, and Y. Totan Penetration of ofloxacin and ciprofloxacin in aqueous humor after topical administration Ophthalmic Surg Lasers 30 1999 465 468
19. N.A. Chaudhry, H.W. Flynn, and T.G. Murray Emerging ciprofloxacin- resistant Pseudomonas aeruginosa Am J Ophthalmol 128 1999 509 510
20. K.M. Colleaux, and W.K. Hamilton Effect of prophylactic antibiotics and incision type on the incidence of endophthalmitis after cataract surgery Can J Ophthalmol 35 2000 373 378
21. D. Croisier, M. Etienne, and E. Bergoin Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy Antimicrob Agents Chemother 48 2004 1699 1707
22. J.J. Dajcs, J.M. Moreau, and D.W. Stroman The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis Curr Eye Res 23 2001 60 63
23. J.J. Dajcs, J.M. Moreau, and B.A. Thibodeaux Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis Cornea 20 2001 878 880
24. J.J. Dajcs, B.A. Thibodeaux, and M.E. Marquart Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis Antimicrob Agents Chemother 48 2004 1948 1952
25. A. Dalhoff Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118 Clin Infect Dis 32 Suppl 1 2001 S16 S22
26. A. Dalhoff, U. Petersen, and R. Endermann In vitro activity of BAY 12-8039, a new 8-methoxyquinolone Chemotherapy 42 1996 410 425
27. M.T. Daporta, J.L. Muñoz Bellido, and G.Y. Guirao In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae Int J Antimicrob Agents 24 2004 185 187
28. T.E. Daum, D.R. Schaberg, and M.S. Terpenning Increasing resistance of Staphylococcus aureus to ciprofloxacin Antimicrob Agents Chemother 34 1990 1862 1863
29. Y. Dong, X. Zhao, and J. Domagala Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus Antimicrob Agents Chemother 43 1999 1756 1758
30. K. Drlica The mutant selection window and antimicrobial resistance J Antimicrob Chemother 52 2003 11 17
31. K. Drlica Mechanism of fluoroquinolone action Curr Opin Microbiol 2 1999 504 508
32. K. Drlica, and D.C. Hooper Mechanisms of quinolone action D.C. Hooper E. Ethan Rubinstein Quinolone Antimicrobial Agents 2003 ASM Press Washington, DC 3, chap 2, pp 19-40
33. K. Drlica, and M. Malik Fluoroquinolones: action and resistance Curr Top Med Chem 3 2003 249 282
34. K. Drlica, and X. Zhao DNA topoisomerase IV as a quinolone target Curr Opin Antiinfect Drugs 1 1999 435 442
35. K. Drlica, and X. Zhao DNA gyrase, topoisomerase IV, and the 4-quinolones Microbiol Mol Biol Rev 61 1997 377 392
36. L. Ferrero, B. Cameron, and J. Crouzet Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus Antimicrob Agents Chemother 39 1995 1554 1558
37. L. Ferrero, B. Cameron, and B. Manse Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones Mol Microbiol 13 1994 641 653
38. Fisher LM, Heaton VJ: Dual activity of fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 51:463-4;author reply 464-5, 2003
39. B. Fournier, and D.C. Hooper Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity Antimicrob Agents Chemother 42 1998 121 128
40. B. Fournier, X. Zhao, and T. Lu Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis Antimicrob Agents Chemother 44 2000 2160 2165
41. J.C. Fung-Tomc, B. Minassian, and B. Kolek Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756 Antimicrob Agents Chemother 44 2000 3351 3356
42. J.A. García-Rodríguez, and A.C. Gómez García The microbiology of moxifloxacin Drugs Today (Barc) 36 2000 215 227
43. P. Garg, S. Sharma, and G.N. Rao Ciprofloxacin-resistant Pseudomonas keratitis Ophthalmology 106 1999 1319 1323
44. S.H. Gillespie, and O. Billington Activity of moxifloxacin against mycobacteria J Antimicrob Chemother 44 1999 393 395
45. E.J. Goldstein, D.M. Citron, and M. Hudspeth In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans Antimicrob Agents Chemother 41 1997 1552 1557
46. M.H. Goldstein, R.P. Kowalski, and Y.J. Gordon Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review Ophthalmology 106 1999 1313 1318
47. L.R. Groden, B. Murphy, and J. Rodnite Lid flora in blepharitis Cornea 10 1991 50 53
48. D.P. Han, S.R. Wisniewski, and L.A. Wilson Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study Am J Ophthalmol 122 1996 1 17
49. S. Hanioglu-Kargi, N. Basci, and H. Soysal The penetration of ofloxacin into human aqueous humor given by various routes Eur J Ophthalmol 8 1998 33 36
50. S.M. Hariprasad, K.J. Blinder, and G.K. Shah Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous Arch Ophthalmol 123 2005 39 44
51. V.J. Heaton, J.E. Ambler, and L.M. Fisher Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro Antimicrob Agents Chemother 44 2000 3112 3117
52. H. Hiasa, D.O. Yousef, and K.J. Marians DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex J Biol Chem 271 1996 26424 26429
53. K. Hirai, H. Aoyana, and T. Irikura Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli Antimicrob Agents Chemother 29 1985 535 538
54. J.A. Hoogkamp-Korstanje, and J. Roelofs-Willemse Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates J Antimicrob Chemother 45 2000 31 39
55. C. Hooper Mechanisms of fluoroquinolone resistance Drug Resist Update 2 1999 38 55
56. D.C. Hooper E. Rubinstein Quinolone Antimicrobial Agents 3 2003 ASM Press Washington, DC
57. D.G. Hwang Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones Surv Ophthalmol 49 Suppl 2 2004 S79 S83
58. R.D. Isaacs, P.J. Kunke, R.L. Cohen, and J.W. Smith Ciprofloxacin resistance in epidemic methicillin-resistant Staphylococcus aureus Lancet 2 1988 843
59. M.E. Jones, A.M. Staples, and I. Critchley Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States Antimicrob Agents Chemother 44 2000 2645 2652
60. J.H. Jorgensen, and J.D. Turnidge Susceptibility test methods: Dilution and disk diffusion methods P.R. Murray Manual of Clinical Microbiology 8th ed. 2003 ASM Press Washington, DC 1108 1128
61. C.L. Karp, S.S. Tuli, and S.H. Yoo Infectious keratitis after LASIK Ophthalmology 110 2003 503 510
62. Katz HR, Masket S, Lane SS, et al.: Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea (in press)
63. A.B. Khodursky, E.L. Zechiedrich, and N.R. Cozzarelli Topoisomerase IV is a target of quinolones in Escherichia coli Proc Natl Acad Sci USA 92 1995 11801 11805
64. H.P. Knauf, R. Silvany, and P.M. Southern Susceptibility of corneal and conjunctival pathogens to ciprofloxacin Cornea 15 1996 66 71
65. S. Kobayakawa, T. Tochikubo, and A. Tsuji Penetration of levofloxacin into human aqueous humor Ophthalmic Res 35 2003 97 101
66. P. Kotilainen, J. Nikoskelainen, and P. Huovinen Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin J Infect Dis 161 1990 41 44
67. R.P. Kowalski, D.K. Dhaliwal, and L.M. Karenchak Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates Am J Ophthalmol 136 2003 500 505
68. R.P. Kowalski, A.N. Pandya, and L.M. Karenchak An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa Ophthalmology 108 2001 1826 1829
69. R.P. Kowalski, E.G. Romanowski, and F.S. Mah Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model Am J Ophthalmol 138 2004 33 37
70. A. Kramer, and W. Behrens-Baumann Prophylactic use of topical anti-infectives in ophthalmology Ophthalmologica 211 Suppl 1 1997 68 76
71. N. Kurokawa, K. Hayashi, and M. Konishi Increasing ofloxacin resistance of bacterial flora from conjunctival sac of preoperative ophthalmic patients in Japan Jpn J Ophthalmol 46 2001 586 589
72. J.M. Levine, R.J. Noecker, and L.C. Lane Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing J Cataract Refract Surg 30 2004 2177 2182
73. D.E. Low Quinolone resistance and its clinical relevance D.C. Hooper E. Ethan Rubinstein Quinolone Antimicrobial Agents 3, chap 23 2003 ASM Press Washington, DC 355 386
74. P. Maple, J. Hamilton-Miller, and W. Brumfitt Ciprofloxacin resistance in methicillin- and gentamicin-resistant Staphylococcus aureus Eur J Clin Microbiol Infect Dis 8 1989 622 624
75. F.B. Marangon, D. Miller, and M.S. Muallem Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis Am J Ophthalmol 137 2004 453 458
76. L. Martínez-Martínez, A. Pascual, and G.A. Jacoby Quinolone resistance from a transferable plasmid Lancet 351 1998 797 799
77. S. Masket Preventing, diagnosing, and treating endophthalmitis J Cataract Refract Surg 24 1998 725 726
78. R. Mather, L.M. Karenchak, and E.G. Romanowski Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics Am J Ophthalmol 133 2002 463 466
79. R. Mather, J.M. Stewart, and T. Prabriputaloong The effect of cataract surgery on ocular levels of topical moxifloxacin Am J Ophthalmol 138 2004 554 559
80. J.J. Miller, I.U. Scott, and H.W. Flynn Endophthalmitis caused by Streptococcus pneumoniae Am J Ophthalmol 138 2004 231 236
81. M.H. Miller, and M. Mayers Treatment of eye infections D.C. Hooper E. Ethan Rubinstein Quinolone Antimicrobial Agents 3, chap 18 2003 ASM Press Washington, DC 291 309
82. L.M. Milne, and M.C. Faiers Ciprofloxacin resistance in epidemic methicillin-resistant Staphylococcus aureus Lancet 2 1988 843
83. K. Mizuuchi, L.M. Fisher, and M.H. O'Dea DNA gyrase action involves the introduction of transient double-strand breaks into DNA Proc Natl Acad Sci USA 77 1980 1847 1851
84. Y. Nagaki, S. Hayasaka, and C. Kadoi Bacterial endophthalmitis after small-incision cataract surgery. effect of incision placement and intraocular lens type J Cataract Refract Surg 29 2003 20 26
85. E.Y. Ng, M. Trucksis, and D.C. Hooper Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus Antimicrob Agents Chemother 40 1996 1881 1888
86. R.J. Olson Reducing the risk of postoperative endophthalmitis Surv Ophthalmol 49 Suppl 2 2004 S55 S61
87. X.S. Pan, and L.M. Fisher Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones Antimicrob Agents Chemother 43 1999 1129 1136
88. X.S. Pan, and L.M. Fisher DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae Antimicrob Agents Chemother 42 1998 2810 2816
89. E. Pestova, J.J. Millichap, and G.A. Noskin Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones J Antimicrob Chemother 45 2000 583 590
90. E. Pestova, R. Beyer, and N.P. Cianciotto Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones Antimicrob Agents Chemother 43 1999 2000 2004
91. L.R. Peterson Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity Clin Infect Dis 15 33S3 2001 S180 S186
92. L.J. Piddock, and R. Wise The effect of altered porin expression in Escherichia coli upon susceptibility to 4-quinolones J Antimicrob Chemother 18 1986 547 549
93. M.K. Rhee, R.P. Kowalski, and E.G. Romanowski A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa Am J Ophthalmol 138 2004 226 230
94. S.M. Robertson, M.A. Curtis, and B.A. Schlech Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans Surv Ophthalmol 50 Suppl 1 2005 S32-S45
95. J.M. Rodríguez-Martínez, A. Pascual, and I. García Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type beta-lactamase J Antimicrob Chemother 52 2003 703 706
96. H. Saito Comparative antimycobacterial activity of Bay 12-8039 and gatifloxacin Drugs 58 Suppl 2 1999 400 401
97. F. Schaefer, O. Bruttin, and L. Zografos Bacterial keratitis: a prospective clinical and microbiological study Br J Ophthalmol 85 2001 842 847
98. S. Schaefler Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones J Clin Microbiol 27 1989 335 336
99. W.M. Scheld Maintaining fluoroquinolone class efficacy: review of influencing factors Emerg Infect Dis 9 2003 1651 1654
100. Schlech BA, Wilhelmus KR, Crider JY,, et al. Review: Nontuberculous mycobacterial (NTM) infections of the eye and treatment with topical antibacterial agents. Current Med Res Opinion (in press)
101. F.J. Schmitz, P.G. Higgins, and S. Mayer Activity of quinolones against Gram-positive cocci: mechanisms of drug action and bacterial resistance Eur J Clin Microbiol Infect Dis 21 2002 647 659
102. H. Seppälä, M. Al-Juhaish, and H. Järvinen Effect of prophylactic antibiotics on antimicrobial resistance of viridans streptococci in the normal flora of cataract surgery patients J Cataract Refract Surg 30 2004 307 315
103. I. Shalit, S.A. Berger, and A. Gorea Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital Antimicrob Agents Chemother 33 1989 593 594
104. R. Solomon, E.D. Donnenfeld, and H.D. Perry Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor Ophthalmology 112 2005 466 469
105. M.G. Speaker, F.A. Milch, and M.K. Shah Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis Ophthalmology 98 1991 639 649 discussion 650
106. G.E. Stein, S. Schooley, and G.W. Kaatz Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high? Clin Infect Dis 37 2003 1392 1395
107. C.N. Ta, P.R. Egbert, and K. Singh Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery Ophthalmology 109 2002 2036 2040 discussion 2040-1
108. M. Takahata, M. Shimakura, and R. Hori In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae Antimicrob Agents Chemother 45 2001 312 315
109. M. Takei, H. Fukuda, and R. Kishii Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition Antimicrob Agents Chemother 45 2001 3544 3547
110. J. Tankovic, R. Bachoual, and S. Ouabdesselam In-vitroactivity of moxifloxacin against fluoroquinolone-resistant strains of aerobic Gram-negative bacilli and Enterococcus faecalis J Antimicrob Chemother 43 Suppl B 1999 19 23
111. C. Thauvin-Eliopoulos, and G.M. Eliopoulos Activity in vitro of the quionolones D.C. Hooper E. Ethan Rubinstein Quinolone Antimicrobial Agents 2003 ASM Press Washington, DC ed 3, chap 5, 91-111
112. B.A. Thibodeaux, J.J. Dajcs, and A.R. Caballero Quantitative comparison of fluoroquinolone therapies of experimental Gram-negative bacterial keratitis Curr Eye Res 28 2004 337 342
113. J.H. Tran, and G.A. Jacoby Mechanism of plasmid-mediated quinolone resistance Proc Natl Acad Sci USA 99 2002 5638 5642
114. S.J. Tuft, and M. Matheson In vitro antibiotic resistance in bacterial keratitis in London Br J Ophthalmol 84 2000 687 691
115. T. Tungsiripat, M.A. Sarayba, and M.B. Kaufman Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model Am J Ophthalmol 136 2003 76 81
116. J.C. Wang DNA topoisomerases Annu Rev Biochem 65 1996 635 692
117. K. Watanabe, K. Numata-Watanabe, and S. Hayasaka Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas Ophthalmic Res 33 2001 136 139
118. H.C. Wegener, and J. Engberg Veterinary use of quinolones and impact on human infections D.C. Hooper E. Rubinstein Quinolone Antimicrobial Agents 3rd ed. 2003 ASM Press Washington, DC 387 403
119. H.G. Wetzstein, N. Schmeer, and W. Karl Degradation of the fluoroquinolone enrofloxacin by the brown rot fungus Gloeophyllum striatum: identification of metabolites Appl Environ Microbiol 63 1997 4272 4281
120. C.J. Willmott, and A. Maxwell A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex Antimicrob Agents Chemother 37 1993 126 127
121. R. Wise Maximizing efficacy and reducing the emergence of resistance J Antimicrob Chemother 51 Suppl 2003 S37 S42
122. G. Yague, J.E. Morris, and X.S. Pan Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones Antimicrob Agents Chemother 46 2002 413 419
123. I.S. Yalvac, N.E. Basci, and A. Bozkurt Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous J Cataract Refract Surg 29 2003 487 491
124. S.C. Yang, P.R. Hsueh, and H.C. Lai High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan Antimicrob Agents Chemother 47 2003 1958 1962
125. H. Yoshida, M. Bogaki, and M. Nakamura Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli Antimicrob Agents Chemother 35 1991 1647 1650
126. H. Yoshida, M. Bogaki, and M. Nakamura Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli Antimicrob Agents Chemother 34 1990 1271 1272
127. X. Zhao, and K. Drlica Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoro - quinolone studies Clin Infect Dis 33 Suppl 3 2001 S147 S156